Globus Medical, Inc. (GMED) Price Target Analysis

Updated Jun 18, 2026

Analyst Rating: Buy

Based on 36 analysts

38.2% Below Target

GMED trades 38.2% below Wall Street's consensus target of $109.50.

Current Price$79.23

Average Target$109.50

Target

Current

Low$100.00

Median$111.00

High$117.00

Analyst Target Range

Forward P/E16.7x

(Fair)

PEG Ratio0.54

(Undervalued)

Implied Growth+11.7%

(Moderate)

Analyst Spread15.5%

(High Agreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$79.23

Consensus$109.50

High$117.00

Low$100.00

Consensus Scenario Assumptions

The base valuation assumes GMED achieves its forward estimates and maintains a stable P/E multiple of 16.7x. This scenario reflects the blended consensus of 36 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 36 published analyst recommendations for GMED

27/36 analysts are bullish

BearishBullish

Weighted analyst sentiment score based on 36 ratings

ConsensusBuy

Coverage36 Analysts

Net Score+36

Bull / Bear75% / 3%

Strong Buy00%

Buy2775%

Hold822%

Sell13%

Strong Sell00%

Strong Buy

00%

Buy

2775%

Hold

822%

Sell

13%

Strong Sell

00%

Recommendation Mix75% Buy · 22% Hold · 3% Sell

Buy (27)Hold (8)Sell (1)

GMED Price Target Analysis

Updated June 21, 2026

As of June 21, 2026, Globus Medical, Inc. (GMED) has a Wall Street consensus price target of $109.50, based on estimates from 36 covering analysts. With the stock currently trading at $79.23, this represents a potential upside of +38.2%. The company has a market capitalization of $10.69B.

Analyst price targets range from a low of $100.00 to a high of $117.00, representing a 16% spread in expectations. The median target of $111.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.

The current analyst consensus rating is Buy, with 27 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, GMED trades at a trailing P/E of 20.2x and forward P/E of 16.7x. The forward PEG ratio of 0.54 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +11.7% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $94.72, with bear and bull scenarios of $59.67 and $124.80 respectively. Model confidence stands at 58/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis

Avg Peer Upside

+51.7%

Industry Consensus

Avg Forward P/E

19.7x

(Fair)

Peers with Coverage

9 / 10

Active Analyst Tracking

Company	Market Cap	Price	Target	Upside Potential	Rating	Fwd P/E	Analysts
SYKStryker Corporation	$117.9B	$307.80	$387.46	+25.9%	Buy	20.5x	51
ZBHZimmer Biomet Holdings, Inc.	$17.2B	$87.97	$96.33	+9.5%	Hold	10.4x	42
ATECAlphatec Holdings, Inc.	$1.3B	$8.81	$18.00	+104.3%	Buy	27.5x	18
XTNTXtant Medical Holdings, Inc.	$62M	$0.44	—	—	—	—	—
MDTMedtronic plc	$101.9B	$79.34	$95.80	+20.7%	Buy	13.3x	51
BSXBoston Scientific Corporation	$67.3B	$45.29	$82.90	+83.0%	Buy	13.5x	44
HOLXHologic, Inc.	$17.0B	$76.01	$78.69	+3.5%	Hold	17.2x	42
NVCRNovoCure Limited	$1.6B	$14.28	$33.00	+131.1%	Buy	—	15
ISRGIntuitive Surgical, Inc.	$144.5B	$406.78	$597.78	+47.0%	Buy	38.9x	55
MMSIMerit Medical Systems, Inc.	$4.0B	$67.22	$94.20	+40.1%	Buy	16.5x	14

GMED — Frequently Asked Questions

Quick answers to the most common questions about buying GMED stock.

What is the GMED stock price target for 2026?

The consensus Wall Street price target for GMED is $109.5, representing 38.2% upside from the current price of $79.23. With 36 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is GMED a buy, sell, or hold?

GMED has a consensus rating of "Buy" based on 36 Wall Street analysts. The rating breakdown is predominantly bullish, with 27 Buy/Strong Buy ratings. The consensus 12-month price target of $109.5 implies 38.2% upside from current levels.

Is GMED stock overvalued or undervalued?

With a forward P/E of 16.7043x, GMED trades at a relatively low valuation. The consensus target of $109.5 implies 38.2% appreciation, suggesting meaningful undervaluation.

How high can GMED stock go?

The most bullish Wall Street analyst has a price target of $117 for GMED, while the most conservative target is $100. The consensus of $109.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $125 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover GMED stock?

GMED is heavily covered by Wall Street, with 36 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 27 have Buy ratings, 8 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the GMED stock forecast?

The 12-month GMED stock forecast based on 36 Wall Street analysts shows a consensus price target of $109.5, with estimates ranging from $100 (bear case) to $117 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $95, with bear/bull scenarios of $60/$125.

What is GMED's fair value based on fundamentals?

Our quantitative valuation model calculates GMED's fair value at $95 (base case), with a bear case of $60 and bull case of $125. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 58/100.

What is GMED's forward P/E ratio?

GMED trades at a forward P/E ratio of 16.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 20.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy GMED stock?

Wall Street analysts are very optimistic on GMED, with a "Buy" consensus rating and $109.5 price target (38.2% upside). 27 of 36 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do GMED price targets vary so much?

GMED analyst price targets range from $100 to $117, a 16% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $109.5 consensus represents the middle ground. Our model's $60-$125 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools